Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease.

Gellhaar S, Sunnemark D, Eriksson H, Olson L, Galter D.

Cell Tissue Res. 2017 Sep;369(3):445-454. doi: 10.1007/s00441-017-2626-8. Epub 2017 May 2.

2.

Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.

Ridderstad Wollberg A, Ericsson-Dahlstrand A, Juréus A, Ekerot P, Simon S, Nilsson M, Wiklund SJ, Berg AL, Ferm M, Sunnemark D, Johansson R.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5409-14. doi: 10.1073/pnas.1316510111. Epub 2014 Mar 25.

3.

MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies.

Lund H, Gustafsson E, Svensson A, Nilsson M, Berg M, Sunnemark D, von Euler G.

Acta Neuropathol Commun. 2014 Feb 17;2:22. doi: 10.1186/2051-5960-2-22.

4.

Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.

Gu GJ, Lund H, Wu D, Blokzijl A, Classon C, von Euler G, Landegren U, Sunnemark D, Kamali-Moghaddam M.

Neuromolecular Med. 2013 Sep;15(3):458-69. doi: 10.1007/s12017-013-8232-3. Epub 2013 May 12.

PMID:
23666762
5.

Tau-tubulin kinase 1 expression, phosphorylation and co-localization with phospho-Ser422 tau in the Alzheimer's disease brain.

Lund H, Cowburn RF, Gustafsson E, Strömberg K, Svensson A, Dahllund L, Malinowsky D, Sunnemark D.

Brain Pathol. 2013 Jul;23(4):378-89. doi: 10.1111/bpa.12001. Epub 2012 Nov 20.

PMID:
23088643
6.

Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.

Gu GJ, Wu D, Lund H, Sunnemark D, Kvist AJ, Milner R, Eckersley S, Nilsson LN, Agerman K, Landegren U, Kamali-Moghaddam M.

J Alzheimers Dis. 2013;33(3):699-713. doi: 10.3233/JAD-2012-121357.

PMID:
23001711
7.

Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand.

Juréus A, Swahn BM, Sandell J, Jeppsson F, Johnson AE, Johnström P, Neelissen JA, Sunnemark D, Farde L, Svensson SP.

J Neurochem. 2010 Aug;114(3):784-94. doi: 10.1111/j.1471-4159.2010.06812.x. Epub 2010 May 13.

8.

Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis.

Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Wallström E, Lobell A, Brundin L, Lassmann H, Harris RA.

J Leukoc Biol. 2008 Nov;84(5):1248-55. doi: 10.1189/jlb.1207844. Epub 2008 Jul 21.

PMID:
18644848
9.

Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE.

Eltayeb S, Berg AL, Lassmann H, Wallström E, Nilsson M, Olsson T, Ericsson-Dahlstrand A, Sunnemark D.

J Neuroinflammation. 2007 May 7;4:14.

10.

Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice.

Oberg J, Spenger C, Wang FH, Andersson A, Westman E, Skoglund P, Sunnemark D, Norinder U, Klason T, Wahlund LO, Lindberg M.

Neurobiol Aging. 2008 Sep;29(9):1423-33. Epub 2007 Apr 16.

PMID:
17434239
11.

CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin.

Sunnemark D, Eltayeb S, Nilsson M, Wallström E, Lassmann H, Olsson T, Berg AL, Ericsson-Dahlstrand A.

J Neuroinflammation. 2005 Jul 29;2:17.

12.

[Neurological effects of American trypanosomyiasis: clinical aspects].

León-Sarmiento FE, Prada DG, Bayona-Prieto J, Valderrama V, García I, León ME, Sunnemark D.

Biomedica. 2003 Dec;23(4):462-75. Review. Spanish.

PMID:
14968924
13.

Differential expression of the chemokine receptors CX3CR1 and CCR1 by microglia and macrophages in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis.

Sunnemark D, Eltayeb S, Wallström E, Appelsved L, Malmberg A, Lassmann H, Ericsson-Dahlstrand A, Piehl F, Olsson T.

Brain Pathol. 2003 Oct;13(4):617-29.

PMID:
14655765
14.

Dihydropyrimidinase related protein-2 as a biomarker for temperature and time dependent post mortem changes in the mouse brain proteome.

Franzén B, Yang Y, Sunnemark D, Wickman M, Ottervald J, Oppermann M, Sandberg K.

Proteomics. 2003 Oct;3(10):1920-9.

PMID:
14625854
15.

Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease.

Eltayeb S, Sunnemark D, Berg AL, Nordvall G, Malmberg A, Lassmann H, Wallström E, Olsson T, Ericsson-Dahlstrand A.

J Neuroimmunol. 2003 Sep;142(1-2):75-85.

PMID:
14512166
16.

CBA/J mice infected with Trypanosoma cruzi: an experimental model for inflammatory myopathies.

Andersson J, Englund P, Sunnemark D, Dahlstedt A, Westerblad H, Nennesmo I, Orn A, Lundberg IE.

Muscle Nerve. 2003 Apr;27(4):442-8.

PMID:
12661045
17.

Chronic murine Chagas' disease: the impact of host and parasite genotypes.

Andersson J, Orn A, Sunnemark D.

Immunol Lett. 2003 Apr 3;86(2):207-12.

PMID:
12644324
18.

Induction of early atherosclerosis in CBA/J mice by combination of Trypanosoma cruzi infection and a high cholesterol diet.

Sunnemark D, Harris RA, Frostegård J, Orn A.

Atherosclerosis. 2000 Dec;153(2):273-82.

PMID:
11164416
21.
22.

Enhanced prevalence of T cells expressing TCRBV8S2 and TCRBV8S3 in hearts of chronically Trypanosoma cruzi-infected mice.

Sunnemark D, Andersson R, Harris RA, Jeddi-Tehrani M, Orn A.

Immunol Lett. 1998 Feb;60(2-3):171-7.

PMID:
9557960
23.
25.

Organ-specific regulation of interferon-gamma, interleukin-2 and interleukin-2 receptor during murine infection with Trypanosoma cruzi.

Rottenberg ME, Sunnemark D, Leandersson T, Orn A.

Scand J Immunol. 1993 May;37(5):559-68.

PMID:
8484102

Supplemental Content

Loading ...
Support Center